CD163 and diffuse large B-cell lymphoma: used a customized panel of 36 antibodies for DSP from samples of diffuse large B-cell lymphoma (DLBCL) patients pretreated with chemoimmunotherapy (118) and revealed that CD68+CD163+ M2 macrophages showed dramatic negative impacts on prognosis.